These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 12075361)

  • 1. Economic analyses of rubella and rubella vaccines: a global review.
    Hinman AR; Irons B; Lewis M; Kandola K
    Bull World Health Organ; 2002; 80(4):264-70. PubMed ID: 12075361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
    Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
    Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.
    Isaacman DJ; Strutton DR; Kalpas EA; Horowicz-Mehler N; Stern LS; Casciano R; Ciuryla V
    Clin Ther; 2008 Feb; 30(2):341-57. PubMed ID: 18343273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States.
    Zhou F; Reef S; Massoudi M; Papania MJ; Yusuf HR; Bardenheier B; Zimmerman L; McCauley MM
    J Infect Dis; 2004 May; 189 Suppl 1():S131-45. PubMed ID: 15106102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications.
    Goldie SJ; O'Shea M; Diaz M; Kim SY
    Reprod Health Matters; 2008 Nov; 16(32):86-96. PubMed ID: 19027626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
    Peny JM; Gleizes O; Covilard JP
    Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of Haemophilus influenzae type B vaccination in Indonesia: a cost-effectiveness analysis.
    Broughton EI
    J Public Health (Oxf); 2007 Dec; 29(4):441-8. PubMed ID: 17875589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global use of rubella vaccines, 1980-2009.
    Strebel PM; Gacic-Dobo M; Reef S; Cochi SL
    J Infect Dis; 2011 Sep; 204 Suppl 2():S579-84. PubMed ID: 21954250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health economics of rubella: a systematic review to assess the value of rubella vaccination.
    Babigumira JB; Morgan I; Levin A
    BMC Public Health; 2013 Apr; 13():406. PubMed ID: 23627715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost-effectiveness of introducing hepatitis B vaccine into infant immunization services in Mozambique.
    Griffiths UK; Hutton G; Das Dores Pascoal E
    Health Policy Plan; 2005 Jan; 20(1):50-9. PubMed ID: 15689430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-benefit comparisons of investments in improved water supply and cholera vaccination programs.
    Jeuland M; Whittington D
    Vaccine; 2009 May; 27(23):3109-20. PubMed ID: 19428925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measles and rubella in the World Health Organization European region: diversity creates challenges.
    Spika JS; Wassilak S; Pebody R; Lipskaya G; Deshevoi S; Guris D; Emiroglu N
    J Infect Dis; 2003 May; 187 Suppl 1():S191-7. PubMed ID: 12721913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries.
    Colantonio L; Gómez JA; Demarteau N; Standaert B; Pichón-Rivière A; Augustovski F
    Vaccine; 2009 Sep; 27(40):5519-29. PubMed ID: 19616499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control of rubella and congenital rubella syndrome (CRS) in developing countries, Part 2: Vaccination against rubella.
    Robertson SE; Cutts FT; Samuel R; Diaz-Ortega JL
    Bull World Health Organ; 1997; 75(1):69-80. PubMed ID: 9141752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of congenital rubella syndrome--what makes sense in 2006?
    Robinson JL; Lee BE; Preiksaitis JK; Plitt S; Tipples GA
    Epidemiol Rev; 2006; 28():81-7. PubMed ID: 16775038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-benefit analysis and immunization programmes in developing countries.
    Creese AL; Henderson RH
    Bull World Health Organ; 1980; 58(3):491-7. PubMed ID: 6774825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost analysis of post-polio certification immunization policies.
    Sangrujee N; Cáceres VM; Cochi SL
    Bull World Health Organ; 2004 Jan; 82(1):9-15. PubMed ID: 15106295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Health and economic benefits of mandatory regular vaccination in Slovakia. IV. Measles, rubella and mumps].
    Hudecková H; Straka S; Avdicová M; Rusnáková S
    Epidemiol Mikrobiol Imunol; 2001 Feb; 50(1):31-5. PubMed ID: 11233671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effectiveness, population-level effects, and heath economics of measles and rubella vaccination].
    Wichmann O; Ultsch B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Sep; 56(9):1260-9. PubMed ID: 23990088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of vaccine manufacturers in developing countries towards global healthcare by providing quality vaccines at affordable prices.
    Jadhav S; Gautam M; Gairola S
    Clin Microbiol Infect; 2014 May; 20 Suppl 5():37-44. PubMed ID: 24476201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.